S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

IXICO Share Forecast, Price & News

GBX 53.50
-0.38 (-0.71%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
78,304 shs
Average Volume
111,741 shs
Market Capitalization
£25.76 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IXI News and Ratings via Email

Sign-up to receive the latest news and ratings for IXICO and its competitors with MarketBeat's FREE daily newsletter.

IXICO logo


IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services in the fields of Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, And Progressive Supranuclear Palsy, Spinocerebellar Ataxia, and Friedreich's Ataxia diseases, as well as other movement disorders and dementias; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.


IXICO (LON:IXI) Stock Passes Below 200 Day Moving Average of $78.02
November 25, 2021 |  americanbankingnews.com
IXICO (LON:IXI) Stock Crosses Below 50-Day Moving Average of $76.96
November 9, 2021 |  americanbankingnews.com
Is Now The Time To Look At Buying IXICO plc (LON:IXI)?
October 25, 2021 |  finance.yahoo.com
Ixico Inks New Contract Worth More Than $750,000
September 22, 2021 |  marketwatch.com
Ixico Gets Contract Win from US Biopharmaceutical Company
September 20, 2021 |  marketwatch.com
See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
£9.89 million
Cash Flow
GBX 14.88 per share
Book Value
GBX 21.70 per share


Pretax Margin




Free Float
Market Cap
£25.76 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)


Overall MarketRank

1.08 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

IXICO (LON:IXI) Frequently Asked Questions

Is IXICO a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IXICO in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IXICO stock.
View analyst ratings for IXICO
or view top-rated stocks.

How has IXICO's stock been impacted by COVID-19?

IXICO's stock was trading at GBX 57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IXI stock has decreased by 6.1% and is now trading at GBX 53.50.
View which stocks have been most impacted by COVID-19

When is IXICO's next earnings date?

IXICO is scheduled to release its next quarterly earnings announcement on Tuesday, December 7th 2021.
View our earnings forecast for IXICO

How were IXICO's earnings last quarter?

IXICO plc (LON:IXI) posted its quarterly earnings results on Wednesday, May, 20th. The company reported $1.01 earnings per share for the quarter.
View IXICO's earnings history

Who are IXICO's key executives?

IXICO's management team includes the following people:
  • Mr. Giulio Cerroni, CEO & Director (Age 59, Pay $537.66k)
  • Mr. Grant Nash, CFO, Company Sec. & Exec. Director
  • Prof. Daniel Rueckert, Co-Founder & Member of Scientific Advisory Board
  • Prof. Derek Lionel Glendon Hill, Co-Founder and Pres of Regulatory Science & External Relations (Age 55)
  • Prof. David Hawkes, Co-Founder & Member of Scientific Advisory Board
  • Prof. Joseph Hajnal, Co-Founder & Member of Scientific Advisory Board
  • Mr. Marcus Thornton, Chief Operating Officer
  • Mr. Mark Austin, Director of Technology
  • Ms. Hannah Esfahanian, HR Mang.
  • Dr. John Hall, Sr. VP of Bus. Devel. (Age 42)

What other stocks do shareholders of IXICO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IXICO investors own include Motif Bio (MTFB), ReNeuron Group (RENE), Pendragon (PDG), EnQuest (ENQ) and Chariot Oil & Gas (CHAR).

What is IXICO's stock symbol?

IXICO trades on the London Stock Exchange (LON) under the ticker symbol "IXI."

How do I buy shares of IXICO?

Shares of IXI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is IXICO's stock price today?

One share of IXI stock can currently be purchased for approximately GBX 53.50.

How much money does IXICO make?

IXICO has a market capitalization of £25.76 million and generates £9.89 million in revenue each year.

How many employees does IXICO have?

IXICO employs 82 workers across the globe.

What is IXICO's official website?

The official website for IXICO is ixico.com.

Where are IXICO's headquarters?

How can I contact IXICO?

IXICO's mailing address is 4th Fl, Griffin Court, 15 Long Lane, LONDON, EC1A 9PN, United Kingdom. The company can be reached via phone at +44-20-37637499.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.